Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Daniel J. Jackson, Leonard B. Bacharier, Peter J. Gergen, Lisa Gagalis, Agustin Calatroni, Stephanie Wellford, Michelle A. Gill, Jeffrey R. Stokes, Andrew H. Liu, Rebecca S. Gruchalla, Robyn T. Cohen, Melanie Makhija, Gurjit K. Khurana Hershey, George O'connor, Jacqueline A. Pongracic, Michael G. Sherenian, Katherine Rivera‐Spoljaric, Edward M. Zoratti, Stephen J. Teach, Meyer Kattan, Cullen M. Dutmer, Hae Jin Kim, Carin Lamm, William J Sheehan, R. Max Segnitz, Kimberly A. Dill‐McFarland, Cynthia M. Visness, Patrice M. Becker, James E. Gern, Christine A. Sorkness, William W. Busse, Matthew C. Altman
Topics & Concepts
MedicineMepolizumabAsthmaExacerbationPlaceboPopulationPediatricsRandomized controlled trialWheezeInternal medicinePhysical therapyEosinophilAlternative medicinePathologyEnvironmental healthAsthma and respiratory diseasesDelphi Technique in ResearchHealth, Environment, Cognitive Aging